[A26-10] Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Addendum to Project A25-128
Last updated 19.03.2026
Project no.:
A26-10
Commission:
Commission awarded on 10.02.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced HER2-positive gastric or GEJ adenocarcinoma who have received 1 prior trastuzumab-based regimen in first-line therapy
Unchanged after addendum: hint of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
https://doi.org/10.60584/A26-10
| Project no. | Title | Status |
|---|---|---|
| A25-128 | Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
19-03-2026 A G-BA decision was published.
G-BA documents on this decision